Novartis Announces Two Phase 3 Positive Results of Cosentyx

Compilenewborn

Recently, Novartis announced the new analysis data of the Phase 3 JUNIPERA study, confirming that the anti-inflammatory drug Cosentyx (common name: secukinumab, secukinumab) has an effect on enthesitis-associated arthritis (ERA) and juvenile silver.

JUNIPERA is a 2-year, three-part, double-blind, placebo-controlled, randomized phase 3 clinical study of drug withdrawal.

In the first treatment period of the study, all patients received Cosentyx 75mg/150mg open-label treatment (prefilled syringe, 75mg for patients with a body weight of <50kg, and 150mg for patients with a body weight of ≥50kg) until the 12th week

The primary endpoint of the study was the flare time in treatment period 2 (week 12 to week 104)

The 2-year results from this study showed that patients treated with Cosentyx had a significantly delayed onset of disease

Without treatment, ERA and JPsA will have a major negative impact on the quality of life of pediatric patients, and may lead to deformities and long-term disability

Novartis has submitted regulatory applications for Cosentyx to treat ERA and JPsA in Europe and the United States, and it is expected to receive the review results in the next few months

The development of pediatric indications is an important part of the Cosentyx clinical development project

Reference source: Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021